
Michaël G Tovey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3859903/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	HypervirulentM. tuberculosisW/Beijing Strains Upregulate Type I IFNs and Increase Expression of Negative Regulators of the Jak-Stat Pathway. Journal of Interferon and Cytokine Research, 2005, 25, 694-701.	1.2	267
2	Pronounced antiviral activity of human interferon on bovine and porcine cells. Nature, 1974, 251, 543-545.	27.8	191
3	Activation of latent Epstein–Barr virus by antibody to human IgM. Nature, 1978, 276, 270-272.	27.8	185
4	A Method for the Large Scale Production of Potent Interferon Preparations. Experimental Biology and Medicine, 1974, 146, 809-815.	2.4	167
5	Identification of the cell multiplication inhibitory factors in interferon preparations as interferons. Nature, 1976, 262, 300-302.	27.8	139
6	Gene Expression in Scrapie. Journal of Biological Chemistry, 1998, 273, 7691-7697.	3.4	139
7	Lethality of interferon preparations for newborn mice. Nature, 1975, 258, 76-78.	27.8	131
8	Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature, 1976, 263, 420-422.	27.8	124
9	Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease. Therapeutic Drug Monitoring, 2013, 35, 530-538.	2.0	104
10	Immunogenicity and other problems associated with the use of biopharmaceuticals. Therapeutic Advances in Drug Safety, 2011, 2, 113-128.	2.4	98
11	Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists. Journal of Immunological Methods, 2011, 373, 229-239.	1.4	91
12	Interferons α and γ induce p53-dependent and p53-independent apoptosis, respectively. Oncogene, 2005, 24, 605-615.	5.9	89
13	Mycobacterial Antigens Exacerbate Disease Manifestations in Mycobacterium tuberculosis-Infected Mice. Infection and Immunity, 2002, 70, 2100-2107.	2.2	88
14	Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy. Journal of Immunology, 2009, 182, 5217-5224.	0.8	86
15	Adjuvant Activity of Cytokines. Methods in Molecular Biology, 2010, 626, 287-309.	0.9	83
16	Inhibition by Interferon of Thymidine Uptake in Chemostat Cultures of L1210 Cells. Intervirology, 1978, 9, 243-252.	2.8	75
17	Targeting Poly(I:C) to the TLR3-Independent Pathway Boosts Effector CD8 T Cell Differentiation through IFN- $\hat{1} \pm l^2$. Journal of Immunology, 2008, 181, 7670-7680.	0.8	64
18	Upon Intranasal Vesicular Stomatitis Virus Infection, Astrocytes in the Olfactory Bulb Are Important Interferon Beta Producers That Protect from Lethal Encephalitis. Journal of Virology, 2015, 89, 2731-2738.	3.4	64

#	Article	IF	CITATIONS
19	Targeting the Effector Site with IFN- $\hat{l} \hat{z}^2$ -Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors. Journal of Immunology, 2008, 180, 1535-1544.	0.8	59
20	Marked enhancement of interferon production in 5-bromodeoxyuridine treated human lymphoblastoid cells. Nature, 1977, 267, 455-457.	27.8	56
21	<i>Cryptosporidium parvum</i> Infection Rapidly Induces a Protective Innate Immune Response Involving Type I Interferon. Journal of Infectious Diseases, 2009, 200, 1548-1555.	4.0	56
22	Molecular mechanisms regulating induction of interleukin-6 gene transcription by interferon-γ. European Journal of Immunology, 1997, 27, 3022-3030.	2.9	55
23	Adjuvant activity of type I interferons. Biological Chemistry, 2008, 389, 541-545.	2.5	53
24	INTERFERON-INDUCED DISEASE IN MICE AND RATS. Annals of the New York Academy of Sciences, 1980, 350, 12-20.	3.8	52
25	Oromucosal Interferon Therapy: Marked Antiviral and Antitumor Activity. Journal of Interferon and Cytokine Research, 1999, 19, 145-155.	1.2	50
26	Interferon and murine leukemia. VII. Therapeutic effect of interferon preparations after diagnosis of lymphoma in akr mice. International Journal of Cancer, 1976, 17, 647-651.	5.1	49
27	The Relationship Between the Interferon α Response and Viral Burden in Primary SIV Infection. AIDS Research and Human Retroviruses, 1996, 12, 1273-1278.	1.1	45
28	Role of endogenous interferon in the anti-tumor effect of poly I·C and statolon as demonstrated by the use of anti-mouse interferon serum. International Journal of Cancer, 1978, 21, 72-77.	5.1	39
29	Identification of Residues of the IFNAR1 Chain of the Type I Human Interferon Receptor Critical for Ligand Binding and Biological Activityâ€. Biochemistry, 2004, 43, 12498-12512.	2.5	36
30	Effect of anti-interferon serum of influenza virus infection in mice. Antiviral Research, 1983, 3, 59-65.	4.1	35
31	Enhanced levels of scrapie responsive gene mRNA in BSE-infected mouse brain. Molecular Brain Research, 2000, 76, 173-179.	2.3	35
32	Molecular Cloning of ADIR , a Novel Interferon Responsive Gene Encoding a Protein Related to the Torsins. Genomics, 2002, 79, 315-325.	2.9	34
33	The κB Enhancer of the Human Interleukin-6 Promoter Is Necessary and Sufficient to Confer an IL-1β and TNF-α Response in Transfected Human Cell Lines: Requirement for Members of the C/EBP Family for Activity. Journal of Interferon and Cytokine Research, 1996, 16, 783-798.	1.2	32
34	Oromucosal Interferon Therapy: Pharmacokinetics and Pharmacodynamics. Journal of Interferon and Cytokine Research, 1999, 19, 157-169.	1.2	32
35	Scrg1 is induced in TSE and brain injuries, and associated with autophagy. European Journal of Neuroscience, 2005, 22, 133-146.	2.6	32
36	Interferon and Cell Division VII. Inhibitory Effect of Highly Purified Interferon Preparations on the Multiplication of Leukemia L 1210 Cells, Experimental Biology and Medicine, 1973, 142, 7-10	2.4	31

#	Article	IF	CITATIONS
37	Rapid increase in guanosine 3′,5′-cyclic-monophosphate in interferon-treated mouse leukemia L1210 cells: Relationship to the development of the antiviral state and inhibition of cell multiplication. Virology, 1981, 115, 272-281.	2.4	30
38	Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10486-10491.	7.1	30
39	Presence of an abnormal ? 2-microglobulin mRNA in Daudi cells: Induction by interferon. Immunogenetics, 1983, 17, 125-131.	2.4	29
40	Concomitant type I IFN receptorâ€ŧriggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankaraâ€induced Tâ€cell expansion. European Journal of Immunology, 2010, 40, 2769-2777.	2.9	29
41	Adjuvant activity of interferon alpha: mechanism(s) of action. Vaccine, 2006, 24, S46-S47.	3.8	28
42	Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. IV. Definition of optimal treatment regimens. International Journal of Cancer, 1986, 38, 251-257.	5.1	25
43	Genes for Interleukin-1, Interleukin-6, and Tumor Necrosis Factor are Expressed at Markedly Reduced Levels in the Livers of Patients with Severe Liver Disease. Autoimmunity, 1991, 10, 297-310.	2.6	25
44	Characterization of the Human Analogue of a Scrapie-responsive Gene. Journal of Biological Chemistry, 1998, 273, 18015-18018.	3.4	25
45	Interleukin-6 repression is associated with a distinctive chromatin structure of the gene. Nucleic Acids Research, 1999, 27, 4483-4490.	14.5	25
46	SCRG1, a Potential Marker of Autophagy in TSE. Autophagy, 2006, 2, 58-60.	9.1	25
47	TL1A: A mediator of gut inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8303-8304.	7.1	25
48	The essential role of endogenous IFN α/β in the anti-metastatic action of sensitized T lymphocytes in mice injected with friend erythroleukemia cells. International Journal of Cancer, 1995, 63, 726-731.	5.1	24
49	Safety, Tolerability, and Immunogenicity of Interferons. Pharmaceuticals, 2010, 3, 1162-1186.	3.8	24
50	Constitutive expression of specific interferon isotypes in peripheral blood leukocytes from normal individuals and in promonocytic U937 cells. Journal of Leukocyte Biology, 1996, 60, 137-146.	3.3	23
51	Overcoming immunogenicity associated with the use of biopharmaceuticals. Expert Review of Clinical Pharmacology, 2011, 4, 623-631.	3.1	23
52	Infection by ME7 prion is not modified in transgenic mice expressing the yeast chaperone Hsp104 in neurons. Neuroscience Letters, 2006, 405, 181-185.	2.1	22
53	Effect of sublingual administration of interferon-α on the immune response to influenza vaccination in institutionalized elderly individuals. Vaccine, 2008, 26, 4073-4079.	3.8	22
54	Characterization of a Domain of a Human Type I Interferon Receptor Protein Involved in Ligand Binding. Journal of Interferon and Cytokine Research, 1995, 15, 205-211.	1.2	21

#	Article	IF	CITATIONS
55	Mucosal Cytokine Therapy: Marked Antiviral and Antitumor Activity. Journal of Interferon and Cytokine Research, 1999, 19, 911-921.	1.2	21
56	THE EFFECT OF INTERFERON ON CYCLIC NUCLEOTIDES. Annals of the New York Academy of Sciences, 1980, 350, 266-278.	3.8	18
57	GAAPâ€1: a transcriptional activator of p53 and IRFâ€1 possesses proâ€apoptotic activity. EMBO Reports, 2002, 3, 153-158.	4.5	18
58	Scrg1, a novel protein of the CNS is targeted to the large dense-core vesicles in neuronal cells. European Journal of Neuroscience, 2003, 18, 2449-2459.	2.6	18
59	Type I Interferons Mediate the Innate Cytokine Response to Recombinant Fowlpox Virus but Not the Induction of Plasmacytoid Dendritic Cell-Dependent Adaptive Immunity. Journal of Virology, 2010, 84, 6549-6563.	3.4	18
60	Antitumor Effect of Combined Interferon and Hyperthermia in Mice. Experimental Biology and Medicine, 1982, 169, 413-415.	2.4	17
61	Use of a Standardized MxA Protein Measurement-Based Assay for Validation of Assays for the Assessment of Neutralizing Antibodies Against Interferon-1². Journal of Interferon and Cytokine Research, 2013, 33, 660-671.	1.2	17
62	The Cultivation of Animal Cells in the Chemostat: Application to the Study of Tumor Cell Multiplication. Advances in Cancer Research, 1980, 33, 1-37.	5.0	16
63	An Essential Role for IFN-α in the Overexpression of Fas Ligand on MRL/lpr Lymphocytes and on Their Spontaneous Fas-Mediated Cytotoxic Potential. Journal of Interferon and Cytokine Research, 2004, 24, 717-728.	1.2	16
64	One-step assay for quantification of neutralizing antibodies to biopharmaceuticals. Journal of Immunological Methods, 2010, 356, 18-28.	1.4	16
65	Effect of Oromucosal Administration of IFN-α on Allergic Sensitization and the Hypersensitive Inflammatory Response in Animals Sensitized to Ragweed Pollen. Journal of Interferon and Cytokine Research, 2001, 21, 583-593.	1.2	15
66	A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies. Journal of Immunology Research, 2017, 2017, 1-19.	2.2	15
67	Prolonged Allograft Survival in Cynomolgus Monkeys Treated with a Monoclonal Antibody to the Human Type I Interferon Receptor and Low Doses of Cyclosporine. Journal of Interferon and Cytokine Research, 1998, 18, 273-284.	1.2	14
68	Mouse Scrapie Responsive Gene 1 (Scrg1): Genomic Organization, Physical Linkage to Sap30, Genetic Mapping on Chromosome 8, and Expression in Neuronal Primary Cell Cultures. Genomics, 2000, 70, 140-149.	2.9	14
69	Oromucosal Interferon Therapy: Relationship Between Antiviral Activity and Viral Load. Journal of Interferon and Cytokine Research, 2001, 21, 575-581.	1.2	14
70	Type I interferon subtypes produced by human peripheral mononuclear cells from one normal donor stimulated by viral and non-viral inducing factors. European Cytokine Network, 2007, 18, 108-14.	2.0	14
71	Improvement of Normothermic Rat Liver Ischemia/Reperfusion by Muramyl Dipeptide. Journal of Surgical Research, 1998, 80, 339-344.	1.6	13
72	Identification of a Novel Transcriptional Regulatory Element Common to the p53 and Interferon Regulatory Factor 1 Genes. Journal of Biological Chemistry, 1997, 272, 29801-29809.	3.4	12

#	Article	IF	CITATIONS
73	Involvement of the Gab2 scaffolding adapter in type I interferon signalling. Cellular Signalling, 2007, 19, 2080-2087.	3.6	12
74	IFNAR signaling directly modulates T lymphocyte activity, resulting in milder experimental autoimmune encephalomyelitis development. Journal of Leukocyte Biology, 2016, 99, 175-188.	3.3	12
75	Natural killer cell cytotoxicity: Role of calmodulin. Biochemical and Biophysical Research Communications, 1984, 121, 478-486.	2.1	11
76	Induction of Tolerance to Recombinant Therapeutic Proteins. Journal of Interferon and Cytokine Research, 2001, 21, 1031-1038.	1.2	11
77	Expression of the Genes of Class I Interferons and Interleukin-6 in Individual Cells. Journal of Interferon Research, 1991, 11, 91-103.	1.2	10
78	Interferon-Resistant Daudi Cells Are Deficient in Interferon-α–Induced ISGF3α Activation, but Remain Sensitive to the Interferon-α–Induced Increase in ISGF3γ Content. Journal of Interferon Research, 1993, 13, 377-383.	1.2	8
79	ELECTROPHORETICALLY PURE MOUSE INTERFERON EXERTS MULTIPLE BIOLOGICAL EFFECTS. Annals of the New York Academy of Sciences, 1980, 350, 347-353.	3.8	7
80	Specific Interferon Genes Are Expressed in Individual Cells in the Peritoneum and Bone Marrow of Normal Mice. Journal of Interferon Research, 1992, 12, 27-34.	1.2	7
81	Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticals. Bioanalysis, 2012, 4, 2179-2190.	1.5	7
82	Correlation between growth rate, cell density, and intracellular concentrations of cyclic nucleotides in chemsostat cultures of mouse L1210 cells. Journal of Cellular Physiology, 1980, 105, 363-367.	4.1	6
83	Interferon Enhancement of Natural Killer Cell Cytotoxicity: Role of Cyclic Nucleotides. Journal of Interferon Research, 1982, 2, 549-561.	1.2	6
84	Comparative study of the expression of cellular proteins in uninfected and HIV infected U937 cells using two dimensional SDS polyacrylamide gel electrophoresis. Chemico-Biological Interactions, 1997, 103, 179-186.	4.0	6
85	Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma. Frontiers in Immunology, 2020, 11, 515556.	4.8	5
86	Induction of Epstein-Barr virus early antigen by phytohaemagglutinin in the presence of 5-iodo-2′-deoxyuridine: Application to EBV serology. Journal of Immunological Methods, 1980, 34, 23-29.	1.4	4
87	[47] Use of chemostat culture for the study of the effect of interferon on tumor cell multiplication. Methods in Enzymology, 1981, 79, 391-404.	1.0	3
88	Efficacy and Safety of Orally/Sublingually, Intranasally, and Intraperitoneally Administered Recombinant Murine Interferon in the Treatment of Murine Encephalomyocarditis Virus. Journal of Interferon and Cytokine Research, 2001, 21, 539-545.	1.2	2
89	Expression of ILâ€6 in Normal Individuals and in Patients with Autoimmune Disease ^a . Annals of the New York Academy of Sciences, 1989, 557, 363-373.	3.8	2
90	An Essential Role for IFN-<1>α in the Overexpression of Fas Ligand on MRL/<1>lpr Lymphocytes and on Their Spontaneous Fas-Mediated Cytotoxic Potential. Journal of Interferon and Cytokine Research, 2004, 24, 717-728.	1.2	2

#	Article	IF	CITATIONS
91	WHO international cytokine standards and reference preparations. Journal of Leukocyte Biology, 2010, 88, 425-426.	3.3	1
92	World Health Organization International Cytokine Standards and Reference Preparations. Journal of Interferon and Cytokine Research, 2010, 30, 639-641.	1.2	1
93	Production of TNF-alpha ex vivo is predictive of an immune response to flu vaccination in a frail elderly population. European Cytokine Network, 2016, 27, 63-67.	2.0	1
94	Cyclic GMP levels in interferon treated cells. Antiviral Research, 1985, 5, 127-135.	4.1	0
95	Tandem Repeat Polymers of a Critical Region of the Human Interferon-Î ² Promoter Exhibit a Marked Constitutive Activity and Enhanced Responsiveness to Transcriptional Regulators in Transfected HeLa Cells. Journal of Interferon Research, 1992, 12, 377-387.	1.2	0
96	Immunotherapy of Multiple Sclerosis. Journal of Interferon and Cytokine Research, 2010, 30, 713-714.	1.2	0
97	Introduction: Lessons Learnt from the Use of Cytokines and Cytokine Antagonists. Journal of Interferon and Cytokine Research, 2014, 34, 921-922.	1.2	0